

File No: BIO/CT/24/000009
Government of India
Directorate General of Health Services
Central Drugs Standard Control Organization
(Biological Division)

From:

The Drugs Controller General, India
Directorate General of Health Services,

FDA Bhawan, Kotla Road,
New Delhi-110002

Date:09.04.2024

To,

M/s Mankind Pharma Ltd.,
208, Okhla Industrial Estate, Phase III,
New Delhi (India) – 110020

Subject: Application for grant of permission to conduct Phase-III clinical trial entitled – “A Randomized, Open-label, Phase III Study to Compare the Efficacy and Safety of RapilinTM 30 (30% Insulin Aspart and 70% Insulin Aspart Protamine suspension) Injection with NovoMix 30 (30% Insulin Aspart and 70% Insulin Aspart Protamine suspension) Injection in Adult Patients of Type 2 Diabetes Mellitus” vide protocol No. CCS/INS/21/v3, Version 3 dated 26th Feb 2024-regarding

Ref.: Your Application No. BIO/CT04/FF/2024/41652 dated 02-Feb-2024

Sir,

With reference to your Application No.: BIO/CT04/FF/2024/41652 dated 02-Feb-2024, please find enclosed herewith the permission in Form CT-06 for conduct of subject clinical trial under the provisions of New Drugs and Clinical Trial Rules, 2019.

The permission granted by the Central Licensing Authority to conduct clinical trial under this Chapter shall be subject to following conditions, namely:

- (I) Clinical trial at each site shall be initiated after approval of the clinical trial protocol and other related documents by the Ethics Committee of that site, registered with the Central Licensing Authority under rule 8;
- (II) Where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of rule 7:
Provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be:
Provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site;
- (III) In case an ethics committee of a clinical trial site rejects the approval of the protocol, the details of the same shall be submitted to the Central Licensing Authority prior to seeking approval of another Ethics Committee for the protocol for conduct of the clinical trial at the same site;
- (IV) The Central Licensing Authority shall be informed about the approval granted by the Ethics Committee within a period of fifteen working days of the grant of such approval;
- (V) Clinical trial shall be registered with the Clinical Trial Registry of India maintained by the Indian Council of Medical Research before enrolling the first subject for the trial;
- (VI) Clinical trial shall be conducted in accordance with the approved clinical trial protocol and other related documents and as per requirements of Good Clinical Practices Guidelines and the provisions of these rules;

- (VII) Status of enrolment of the trial subjects shall be submitted to the Central Licensing Authority on quarterly basis or as appropriate as per the duration of treatment in accordance with the approved clinical trial protocol, whichever is earlier;
- (VIII) Six monthly status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Central Licensing Authority electronically in the SUGAM portal;
- (IX) In case of termination of any clinical trial the detailed reasons for such termination shall be communicated to the Central Licensing Authority within thirty working days of such termination;
- (X) Any report of serious adverse event occurring during clinical trial to a subject of clinical trial, shall, after due analysis, be forwarded to the Central Licensing Authority, the chairperson of the Ethics Committee and the institute where the trial has been conducted within fourteen days of its occurrence as per Table 5 of the Third Schedule and in compliance with the procedures as specified in Chapter VI;
- (XI) In case of injury during clinical trial to the subject of such trial, complete medical management and compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licensing Authority within thirty working days of the receipt of order issued by Central Licensing Authority in accordance with the provisions of the said Chapter;
- (XII) In case of clinical trial related death or permanent disability of any subject of such trial during the trial, compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licensing Authority within thirty working days of receipt of the order issued by the Central Licensing Authority in accordance with the provisions of the said Chapter;
- (XIII) The premises of the sponsor including his representatives and clinical trial sites, shall be open for inspection by officers of the Central Licensing Authority who may be accompanied by officers of the State Licensing Authority or outside experts as authorised by the Central Licensing Authority, to verify compliance of the requirements of these rules and Good Clinical Practices Guidelines, to inspect, search and seize any record, result, document, investigational product, related to clinical trial and furnish reply to query raised by the said officer in relation to clinical trial;
- (XIV) The laboratory owned by any person or a company or any other legal entity and utilised by that person to whom permission for clinical trial has been granted used for research and development, shall be deemed to be registered with the Central Licensing Authority and may be used for test or analysis of any drug for and on behalf of Central Licensing Authority;
- (XV) The Central Licensing Authority may, if considered necessary, impose any other condition in writing with justification, in respect of specific clinical trials, regarding the objective, design, subject population, subject eligibility, assessment, conduct and treatment of such specific clinical trial;
- (XVI) The sponsor and the investigator shall maintain the data integrity of the data generated during clinical trial.
- (XVII) It may kindly be noted that merely granting permission to conduct clinical trial with the drug does not convey or imply that based on the clinical trial data generated with the drug permission to market this drug in the country will automatically be granted to you.
- (XVIII) CSR shall be submitted to this office after completion of the clinical trial.

RAJEEV SINGH
RAGHUVANSHI

Digitally signed by RAJEEV SINGH RAGHUVANSHI
DN: c=IN, o=CENTRAL DRUGS STANDARD CONTROL
ORGANIZATION, ou=RAJEEV SINGH RAGHUVANSHI,
2.5.4.20=RAJEEV SINGH RAGHUVANSHI, email=rajeev69041
015a06564fe0-547763db1c1, postalCode=600034,
st=TAMIL NADU,
serialNumber=657F5E47D940985D8F038DC902D0E1FE
73CFA12A1A126EA94FA5701124A19013, cn=RAJEEV
SINGH RAGHUVANSHI
Date: 2024.04.09 17:05:22 +05'30'

(Dr. Rajeev Singh Raghuvanshi)
Central Licensing Authority

File No: BIO/CT/24/000009
Government of India
Directorate General of Health Services
Central Drugs Standard Control Organization
(Biological Division)

From:

The Drugs Controller General, India
Directorate General of Health Services,

FDA Bhawan Kotla Road,
New Delhi-110002
Date: 09.04.2024

To,

M/s Mankind Pharma Ltd.,
208, Okhla Industrial Estate, Phase III,
New Delhi (India) – 110020

Sir,

With reference to your Application No. BIO/FormCT16/TL/2024/143661 dt. 23-01-2024, please find enclosed herewith the "license to import new drug for conduct of clinical trial as per Protocol No. CCS/INS/21/v3, Version 3 dated 26th Feb 2024" bearing No. **TL/BIO/24/000007** under the provisions of Drugs and Cosmetic Act and Rules to import the drug/drugs mentioned therein.

Kindly acknowledge receipt of this letter and its enclosures.

RAJEEV SINGH
RAGHUVANSHI

Digitally signed by RAJEEV SINGH RAGHUVANSHI
DN: cn=RAJEEV SINGH RAGHUVANSHI,
o=CENTRAL DRUGS STANDARD CONTROL
ORGANIZATION, ou=RAJEEV SINGH RAGHUVANSHI,
2.5.4.20=90c62f6a23e4eafbe8a239774cdeb03c2769
041015a06564fe67f54b765db1cb,
postalCode=600034, st=TAMIL NADU,
serialNumber=657F5E47D940985D8F03BDC902D0E
1FE73CFA12A1A126EA94FA5701124A19013,
cn=RAJEEV SINGH RAGHUVANSHI
Date: 2024.04.09 17:05:31 +05'30'

(Dr. Rajeev Singh Raghuvanshi)
Central Licensing Authority

Copy together with a copy of License No TL/BIO/24/000007

Forwarded for information to:-

1. All port offices

FORM CT-06

(See rules 22, 25, 26, 29 and 30)

**PERMISSION TO CONDUCT CLINICAL TRIAL OF NEW DRUG OR
INVESTIGATIONAL NEW DRUG**

The Central Licensing Authority hereby permits M/s Mankind Pharma Ltd., 208, Okhla Industrial Estate, Phase III, New Delhi (India) – 110020 to conduct clinical trial (Phase-III) of the new drug or investigational new drug study titled “A Randomized, Open-label, Phase III Study to Compare the Efficacy and Safety of Rapilin™ 30 (30% Insulin Aspart and 70% Insulin Aspart Protamine suspension) Injection with NovoMix 30 (30% Insulin Aspart and 70% Insulin Aspart Protamine suspension) Injection in Adult Patients of Type 2 Diabetes Mellitus” vide protocol No. CCS/INS/21/v3, Version 3 dated 26th Feb 2024 in the below mentioned clinical trial sites.

2. Details of new drug and clinical trial site [as per Annexure].


3. This permission is subject to the conditions prescribed in part A of Chapter V of the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940.

Place: New Delhi
Date: 09-Apr-2024

**RAJEEV SINGH
RAGHUVANSHI**

Digitally signed by RAJEEV SINGH RAGHUVANSHI
DN: c=IN, o=CENTRAL DRUGS STANDARD CONTROL
ORGANIZATION, ou=RAJEEV SINGH RAGHUVANSHI,
2.5.4.20=80c026a23e4eaff88a239774cdeb03c2769041
015a06564fe67f54b765db1cb, postalCode=600034,
st=TAMIL NADU,
serialNumber=657F5E47D940985D8F03BDC902D0E1FE
73CFA12A1A126EA94FA5701124A19013, cn=RAJEEV
SINGH RAGHUVANSHI
Date: 2024.04.09 17:05:42 +05'30'

(Dr. Rajeev Singh Raghuvanshi)
Drugs Controller General (India)
Central Licensing Authority
Stamp



Annexure:**Details of new drugs or investigational new drugs:**

Names of the new drug or investigational new drug:	Insulin Aspart Mix (30% Insulin Aspart and 70% Insulin Aspart Protamine suspension) Injection 100 units/ml (Rapilin™ 30)		
Therapeutic class:	Antidiabetic		
Dosage form:	Suspension for injection in 3 mL cartridge		
Composition:	Each ml contains-		
	Component	Pharmacopoeial Reference	Unit formula (per ml)
	Insulin Aspart	Ph. Eur/USP	3.50 mg (100 U)
	Protamine Sulphate	Ph. Eur/USP NF	0.33 mg
	Glycerin	Ph. Eur/USP NF	16 mg
	m-Cresol	Ph. Eur/USP	1.72 mg
	Phenol	Ph. Eur/USP NF	1.50 mg
	Zinc Chloride	Ph. Eur/USP	Eq. to 19.6 µg zinc
	Sodium Chloride	Ph. Eur/USP	0.877 mg
	Sodium Phosphate dibasic anhydrous	Ph. Eur/USP	0.9972 mg
	Hydrochloric acid	Ph. Eur/USP NF	q.s. (pH adjustment)
	Sodium Hydroxide	Ph. Eur/USP NF	q.s. (pH adjustment)
Water for injection	USP	q.s. to 1 ml	
Indications:	Insulin Aspart is indicated to improve glycemic control in adults with diabetes mellitus.		

Details of clinical trial site:

S. No	Name and Address of Clinical Trial Site	Ethics Committee Details	Name of Principal Investigator
1	North Delhi Diabetes and Cardiac Centre 252, Upper Ground Floor, Deepali, Pitampura, New Delhi - 110034	GOOD SOCIETY FOR ETHICAL RESEARCH GOOD SOCIETY FOR ETHICAL RESEARCH, H. NO. -D/129, ST. NO.- 13 OPP - DURGA MANDIR, ASHOK NAGAR SHAHDARA NORTH EAST DELHI, DELHI - 110093 INDIA ECR/69/Indt/DL/2013/RR-19	Dr. Rajeev Chawla
2	Centre for Diabetes & Internal Medicine	GOOD SOCIETY FOR ETHICAL RESEARCH GOOD	Dr. Pawan Kumar Goyal

	C-8/67, Sector – 8 Rohini, New Delhi - 110085	SOCIETY FOR ETHICAL RESEARCH, H. NO. -D/129, ST. NO.- 13 OPP - DURGA MANDIR, ASHOK NAGAR SHAHDARA NORTH EAST DELHI, DELHI - 110093 INDIA ECR/69/Indt/DL/2013/RR-19	
3	Department of Endocrinology, Room No. 43 A, Fourth Floor Dhanvantri OPD Block, S.M.S. Medical College and Attached Hospitals Jawahar Lal Nehru Marg Jaipur – 302004, Rajasthan India	Ethics Committee S.M.S. Medical College and Attached Hospitals J.L.N. Marg Jaipur Rajasthan - 302004 India ECR/26/Inst/RJ/2013/RR-19	Dr. Sanjay Saran
4	Department of Endocrinology & Metabolism, Room No. 303, Biotechnology Building, All India Institute of Medical Sciences, Ansari Nagar, New Delhi - 110029	All India Institute of Medical Sciences Old OT Block, Room No. 102, AIIMS Hospital Ansari Nagar, New Delhi-29, India ECR/538/Inst/DL/2014/RR-20	Dr. Rajesh Khadgavat
5	Department of Endocrinology, All India Institute of Medical Sciences, Basni Industrial Area, Phase-2, Jodhpur – 342005, Rajasthan	INSTITUTIONAL HUMAN ETHICS COMMITTEE All India Institute of Medical Sciences, Basni Jodhpur Jodhpur Rajasthan - 342005 India ECR/866/Inst/RJ/2016/RR-19	Dr. Ravindra Shukla
6	Department of Medicine, Victoria Hospital, Mysore Road, near City Market, New Tharagupet, Bengaluru – 560002, Karnataka	ETHICS COMMITTEE OF BMCRI BANGALORE MEDICAL COLLEGE AND RESEARCH INSTITUTE FORT K R ROAD BENGALURU (Bangalore) Urban Karnataka - 560002 India ECR/302/Inst/KA/2013/RR-20	Dr. Diwakar T. N.

7	Madras Diabetes Research Foundation No. 4, Conran Smith Road Gopalapuram, Chennai - 600086	IEC of Madras Diabetes Research Foundation Madras Diabetes Research Foundation 4, Conran Smith Road Gopalapuram Chennai Chennai, Tamil Nadu - 600086 India ECR/194/Inst/TN/2013/RR-19	Dr. V Mohan
8	Department of Medicine, B. J. Govt Medical College and Sassoon General Hospital, Station Rd, Agarkar Nagar, Pune – 411001, Maharashtra	Ethics Committee B J Medical College and SGH B J Medical College and Sassoon General Hospital Jai Prakash Narayan Road Pune Maharashtra – 411001, India ECR/433/Inst/MH/2013/RR-19	Dr. Rohidas T Borse
9	Poona Hospital & Research Centre L. B. Shastri Road 27, Sadashiv Peth, Pune – 411030, Maharashtra	Ethics Committee Poona Hospital Research Centre Poona Hospital and Research Centre 27 Sadashiv peth Lal Bahadur Shastri Road Pune Maharashtra – 411030, India ECR/327/Inst/MH/2013/RR-19	Dr. Mohan Magdum
10	MMF Hospital Association Joshi Hospital, 778 Shivaji Nagar Opposite Kamala Nehru Park, Pune – 411004, Maharashtra	IEC MAHARASHTRA MEDICAL RESEARCH SOCIETY Maharashtra Medical Foundation, Pune. Joshi Hospital 778 Shivaji Nagar, Pune Maharashtra – 411004, India ECR/311/Inst/MH/2013/RR-19	Dr. Narendra Javadekar
11	Diabetes care and Hormone Clinic, 1&2, Gandhi Park, Near Nehru Nagar Cross Roads, Ambawadi, Ahmedabad – 380015, Gujarat	Institutional Ethics Committee Aatman Hospital 5, Anveshan Row House, Opp Umiya Mata Mandir Bopal-Ghuma Main Road, Bopal Ahmedabad, Gujarat - 380058 India ECR/1565/Inst/GJ/2021	Dr. Banshi Saboo

12	METTA Care Clinic, 18/18, Dover Lane, Ballygunge, Kolkata – 700029, West Bengal	Human Research Ethics Committee – AARC Allergy And Asthma Research Centre, 48/7 Purna Das Road, Kolkata West Bengal - 700029 India ECR/360/Indt/WB/2022	Dr. Debasis Basu
----	--	--	------------------

